Amneal Pharmaceuticals receives FDA acceptance for Spironolactone HCl tablets Amneal Pharmaceuticals, LLC is very happy to announce that it has received U.S. FDA approval to manufacture Spironolactone HCl tablets in 25 mg, 50 mg and 100 mg strengths effective July 2, 2010 http://cialiscanadian.org/reviews ., a unit of Pfizer Inc.). Annual U.S. Product sales of Spironolactone HCl had been $91 MM as of December 2009 relating to IMS Health marketplace data. Spironolactone HCl is usually a synthetic 17-lactone medication that is a renal competitive aldosterone antagonist in the class of pharmaceuticals known as potassium-sparing diuretics.
‘The BiTE antibody provides an innovative approach to cancers therapy,’ said Roger M. Perlmutter, M.D., Ph.D., executive vice president of Study and Development at Amgen. ‘Amgen is very happy to collaborate with the Micromet scientific group to deploy this technology against targets for the treatment of solid tumors. Micromet is also eligible to receive up to double-digit royalties on worldwide net sales. For the next BiTE program, Micromet can be eligible to receive an additional money payment upon initiation of this program, milestones, advancement and royalties funding comparable to the first program. All expected costs associated with the research, commercialization and advancement of the BiTE antibodies will end up being borne by Amgen.